Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Infliximab and methotrexate in the treatment of rheumatoid arthritis

Article Abstract:

Intravenous infliximab may stop the progression of joint damage in patients with rheumatoid arthritis when used in combination with methotrexate. Infliximab is a monoclonal antibody that blocks the activity of tumor necrosis factor.

Author: Smolen, Josef S., Lipsky, Peter E., Heijde, Desiree M.F.M. van der, St. Clair, E. William, Furst, Daniel E., Breedveld, Ferdinand C., Kalden, Joachim R., Weisman, Michael, Emery, Paul, Feldmann, Marc, Harriman, Gregory R., Maini, Ravinder N.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Evaluation, Product/Service Evaluation, Methotrexate, Remicade (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

Article Abstract:

An experimental drug called CTLA4Ig may benefit many patients with rheumatoid arthritis, especially those who do not respond to methotrexate. This was the conclusion of a study of 339 patients, all of whom were also taking methotrexate. CTLA4Ig was more effective than a placebo, or inactive substance. This drug prevents T cells from becoming activated.

Author: Moreland, Larry W., Emery, Paul, Nuamah, Isaac F., Dougados, Maxime, Russell, Anthony, Kremer, Joel M., Westhovens, Rene, Leon, Marc, Di Giorgio, Eduardo, Alten, Rieke, Steinfeld, Serge, Williams, G. Rhys, Becker, Jean-Claude, Hagerty, David T.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

The rationale for the current boom in anti-TNFalpha treatment: is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?

Article Abstract:

Pharmaceutical companies are developing drugs that block the activity of tumor necrosis factor (TNF) to treat patients with rheumatoid arthritis. TNF is a protein produced by the body that causes inflammation.

Author: Feldmann, Marc, Maini, Ravinder N., Bondeson, Jan, Brennan, Fionula M., Foxwell, Brian M.J.
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1999
Health aspects, Tumor necrosis factor

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy, Rheumatoid arthritis
Similar abstracts:
  • Abstracts: Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV(sub)251 infection of macaques
  • Abstracts: A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor
  • Abstracts: Who cares for the care givers? Lack of health insurance among health and insurance personnel. Smoking and Mental Illness: A Population-Based Prevalence Study
  • Abstracts: Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.